SCHEMBL6525840

SCHEMBL6525840

[NH][C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP1A2 P05177 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
OTC P00480 1/20 0.38
GAA P10253 1/20 0.36
DDAH1 O94760 1/20 0.36
ALB P02768 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
C3AR1 Q16581 1/20 0.31
NPY4R P50391 4/20 0.31
NPY1R P25929 3/20 0.31
NPY2R P49146 3/20 0.31
NPY5R Q15761 3/20 0.31
DPP7 Q9UHL4 1/20 0.31
TSHR P16473 1/20 0.31
HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1118988 1.00 ALOX15 (0.41) ALOX15MEN1KMT2ACYP1A2SMN1; SMN2
Arginine SCHEMBL1790 0.82 OTC (0.56) ALOX15MEN1KMT2ACYP1A2OTC
Arginine SCHEMBL6374054 0.82 OTC (0.56) ALOX15MEN1KMT2ACYP1A2OTC
SCHEMBL11229239 0.82 GPR84 (0.42) ALOX15MEN1KMT2ACYP1A2SMN1; SMN2
Arginine SCHEMBL7928810 0.82 OTC (0.56) ALOX15MEN1KMT2ACYP1A2OTC
Arginine SCHEMBL288132 0.82 OTC (0.56) ALOX15MEN1KMT2ACYP1A2OTC
Arginine SCHEMBL1791 0.82 OTC (0.56) ALOX15MEN1KMT2ACYP1A2OTC
SCHEMBL3351368 0.82 GPR84 (0.42) ALOX15MEN1KMT2ACYP1A2SMN1; SMN2
Arginine SCHEMBL2411547 0.82 OTC (0.56) ALOX15MEN1KMT2ACYP1A2OTC
Arginine SCHEMBL31663499 0.82 OTC (0.56) ALOX15MEN1KMT2ACYP1A2OTC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002334-A1 RALINEPAG PRODRUGS AND USES THEREOF UNITED THERAPEUTICS CORPORATION 2024-01-04 US claimed
WO-2023177877-A1 RALINEPAG PRODRUGS AND USES THEREOF UNITED THERAPEUTICS CORPORATION (US) 2023-09-21 WO claimed
US-20150126527-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2015-05-07 US claimed
US-8895776-B2 Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2014-11-25 US claimed
US-20110053958-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 US claimed
US-20240002334-A1 RALINEPAG PRODRUGS AND USES THEREOF UNITED THERAPEUTICS CORPORATION 2024-01-04 US disclosed
US-20230404954-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2023-12-21 US disclosed
EP-3884934-B1 PHARMACEUTICAL COMPOSITION COMPRISING: 2-(((1R,4R)-4-(((4-CHLOROPHENYL)(PHENYL)CARBAMOYLOXY)METHYL)CYCLOHEXYL)METHOXY)ACETIC ACID ARENA PHARM INC (US) 2023-12-13 EP disclosed
WO-2023177877-A1 RALINEPAG PRODRUGS AND USES THEREOF UNITED THERAPEUTICS CORPORATION (US) 2023-09-21 WO disclosed
CN-110003123-B Modulators of the PGI2 receptor for the treatment of prostacyclin (PGI 2) receptor related disorders 艾尼纳制药公司 2023-06-23 CN disclosed
US-20230121825-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2023-04-20 US disclosed
EP-3884934-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2021-09-29 EP disclosed
US-20170360730-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2017-12-21 US disclosed
EP-2280696-B9 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2016-01-13 EP disclosed
US-20150126527-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2015-05-07 US disclosed
EP-2857015-A1 Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto Arena Pharmaceuticals, Inc. (US) 2015-04-08 EP disclosed
US-8895776-B2 Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2014-11-25 US disclosed
EP-2280696-B1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2014-09-17 EP disclosed
US-20130217706-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-08-22 US disclosed
US-20110053958-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053958-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R ALOX15 92/4885MEN1 3308/4885KMT2A 4434/4885
US-20130217706-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, PTGER2 ALOX15 126/4885MEN1 3214/4885KMT2A 2641/4885
US-20170360730-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R ALOX15 90/4885MEN1 3319/4885KMT2A 4432/4885
US-20230121825-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, PLOD3 ALOX15 63/4885MEN1 3123/4885KMT2A 4525/4885
US-20150126527-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R ALOX15 90/4885MEN1 3319/4885KMT2A 4432/4885
US-20240002334-A1 RALINEPAG PRODRUGS AND USES THEREOF PTGIR, PTGIS, PTGER1 ALOX15 400/4885MEN1 1306/4885KMT2A 2851/4885
US-20230404954-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R ALOX15 92/4885MEN1 3308/4885KMT2A 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.